Reletter
Artwork for The Biopharma Report

The Biopharma Report

The Biopharma Report provides analysis and commentary on M&A, licensing deals, and competition in the pharma/biotech industry.

Platform
Substack
PricingFreemiumPublishesWeekly
Issues14Founded4 years agoLast Issue3 years ago
Active

Read this Newsletter

thebiopharmareport.substack.com
Artwork for The Biopharma Report

Latest Issues

The Biopharma Report #013

Welcome to a new issue of The Biopharma Report!

Hello everyone, before we dive-in I just want to give a quick update. As you might have noticed, I started publishing more regularly and hopefully will keep it up. The last email I sent had a...

3 years ago
11

The Biopharma Report #012

AstraZeneca Acquires Neogene, Novartis Announces Promising Pluvicto Data

Welcome to a new issue of The Biopharma Report!

3 years ago
7
Paid

J&J Drops New Data, Horizon Entertains Offers

Welcome to a new issue of The Biopharma Report!

Johnson and Johnson Announces New Spravato Data

I wouldn’t say that the data is game changing, but it certainly fortifies Spravato’s position in the treatment resistant depression (TRD) s...

3 years ago
12

The Biopharma Report #010

Welcome to a new issue of The Biopharma Report!

Regeneron and CytomX Announce Strategic Research Collaboration in the Field of Conditional Bispecific Therapeutics for the Treatment of Cancer

That’s a deal with a lot of synergy. CytomX...

4 years ago
14

The Biopharma Report #009

Welcome to a new issue of The Biopharma Report!

GSK’s Respiratory Syncytial Virus Older Adult Vaccine Candidate Granted Priority Review by US FDA

That was one busy week in terms of RSV. A few quarters ago it wasn’t necessarily clear wh...

4 years ago
10

Key Facts

Contact Information
Newsletter Author
Number of Subscribers
Find out how many people subscribe to this newsletter.

Audience Metrics

Subscribers, engagement, traffic and sponsorship for The Biopharma Report.

SubscribersMonthly Web VisitsAccepts Sponsors
Estimated Cost per Ad

Authors

The writers behind this newsletter.

  • The Biopharma Report

    Clinician turned CEO of a biopharma consulting firm.

  • Frequently Asked Questions

    How can I access the email archive for The Biopharma Report?

    You can find recent issues that have been published by The Biopharma Report on Reletter by scrolling up to where it says Latest Issues. Tap on the link for any of the most recent emails or hit More Issues to see older ones.

    How many subscribers does The Biopharma Report have?

    To see how many people subscribe to The Biopharma Report, simply upgrade your Reletter account. We provide readership numbers and lots of other stats for this newsletter so you can decide if it's worth reaching out to.

    How can I advertise in The Biopharma Report?

    Newsletter advertising can be extremely effective when it's done right. Before you pitch The Biopharma Report as a potential sponsor or partner, make sure that you've done your research and checked its newsletter stats with Reletter.

    Then, personalize one of our winning pitching templates and send it to the right person using the contact info provided.

    How much does it cost to sponsor a publication like The Biopharma Report?

    Newsletter ad rates (or CPM) vary depending on many factors, including industry, number of subscribers, open rate, ad placement and more.

    To find out how much an ad will cost, contact The Biopharma Report using the contact information provided and ask for a copy of their media kit.

    How can I find newsletters related to The Biopharma Report?

    Scroll up to where it says Related Newsletters to see other publications like The Biopharma Report. You can also search our email newsletter directory to discover other newsletters that cover the topics you're interested in.

    How do I contact The Biopharma Report?

    Reletter provides this newsletter's website URL above, where you will often find their contact information. We also provide links to associated social media accounts and pitching templates so you can reach out fast.